Sucampo Pharmaceuticals to Report Second Quarter 2008 Financial Results on August 14, 2008

2008-08-07 23:38:04 -

- Westwicke Partners John Woolford, 410-321-9653 john.woolford@westwickepartners.com Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) will release its second quarter 2008 financial results before the opening of the market on Thursday, August 14, 2008. Sucampo will host a conference call for investors on Monday, August 18, 2008 at 10:00 a.m. EDT.

Ryuji Ueno, M.D., Ph.D., Ph.D., Founder, Chairman and Chief Executive Officer of

Sucampo Pharmaceuticals, will lead the call, during which management will discuss the Company's financial results, business outlook and growth strategy.

To participate on the live call, please dial (800) 299-6183 (domestic) or (617) 801-9713 (international). The conference passcode is 14471349. A live and archived audio webcast of the call will be available via the "For Investors" page of the Sucampo Pharmaceuticals website, www.sucampo.com. Please dial in or log on through Sucampo Pharmaceuticals' website approximately 10 minutes prior to the scheduled start time.

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc., a specialty biopharmaceutical company based in Bethesda, Md., focuses on the development and commercialization of medicines based on prostones. The therapeutic potential of prostones, which are bio-lipids that occur naturally in the human body, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' Chairman and Chief Executive Officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding Chief Executive Officer and advisor, international business development.

Sucampo Pharmaceuticals is marketing AMITIZA(R) (lubiprostone) 24 mcg in the U.S. for chronic idiopathic constipation in adults and AMITIZA(R) (lubiprostone) 8 mcg in the U.S. to treat irritable bowel syndrome with constipation in adult women and is developing the drug for additional gastrointestinal disorders with large potential markets. In addition, Sucampo Pharmaceuticals has a robust pipeline of compounds with the potential to target underserved diseases affecting millions of patients worldwide. Sucampo Pharmaceuticals has two wholly owned subsidiaries: Sucampo Pharma Europe, Ltd., headquartered in Oxford, UK with a branch office in Basel, Switzerland, and Sucampo Pharma, Ltd., located in Tokyo and Osaka, Japan. To learn more about Sucampo Pharmaceuticals and its products, visit www.sucampo.com.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Sucampo Pharmaceuticals are forward-looking statements made under the provisions of The Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the words "project," "believe," "anticipate," "plan," "expect," "estimate," "intend," "should," "would," "could," "will," "may" or other similar expressions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors described in Sucampo Pharmaceuticals' filings with the Securities and Exchange Commission (SEC), including the annual report on Form 10-K for the year ended December 31, 2007 and other periodic reports filed with the SEC. Any forward-looking statements in this press release, including statements regarding the expansion in the number of indications addressed by AMITIZA(R) 8 mcg, our ability to drive AMITIZA(R) sales growth and build greater brand awareness among patients and physicians, and the future success of our ongoing preclinical studies and clinical trials, represent Sucampo Pharmaceuticals' views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Sucampo Pharmaceuticals anticipates that subsequent events and developments will cause its views to change. However, while Sucampo Pharmaceuticals may elect to update these forward-looking statements publicly at some point in the future, Sucampo Pharmaceuticals specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise.

Conference Call to be Held on August 18, 2008 at 10:00 am EDT